6月30日，据CDE官网消息，重庆华森制药股份有限公司联合申请药品“CX001缓释片”，获得临床试验默示许可，受理号CXHL2500392。
公示信息显示，药品“CX001缓释片”适应症：本品用于治疗带状疱疹后神经痛。
重庆华森制药股份有限公司，成立于1996年，位于重庆市，是一家以从事医药制造业为主的企业。企业注册资本41759.6314万人民币，实缴资本7770万人民币。
通过天眼查大数据分析，重庆华森制药股份有限公司共对外投资了12家企业，参与招投标项目4210次，知识产权方面有商标信息204条，专利信息134条，此外企业还拥有行政许可210个。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.